BAI1

CAS No. 335165-68-9

BAI1( —— )

Catalog No. M20096 CAS No. 335165-68-9

BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 In Stock
5MG 72 In Stock
10MG 115 In Stock
25MG 228 In Stock
50MG 417 In Stock
100MG 614 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BAI1
  • Note
    Research use only, not for human use.
  • Brief Description
    BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).
  • Description
    BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).
  • In Vitro
    Apoptosis Analysis Cell Line:Mouse MEF Concentration:0.3125 μM , 0.625 μM, 1 μM, 1.25 μM, 1.5 μM, 2.5 μM , 3 μM, 4 μM, 5 4 μM, 10 4 μM Incubation Time:8 hours Result:Inhibited cell death in BAX-dependent manner.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bax
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    335165-68-9
  • Formula Weight
    467.2
  • Molecular Formula
    C19H21Br2N3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 15 mg/mL (32.1 mM);Water: Insoluble
  • SMILES
    OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bombrun A et al. 36-dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via Bax channel modulation. J Med Chem. 2003 Oct 9;46(21):4365-8.
molnova catalog
related products
  • Paederosidic acid

    Paederosidic acid has significant anti-tumor anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain and it up-regulates expressions of GAD 65 may be a promising future therapeutic agent for treatment of epilepsy.

  • BCL6-IN-8

    BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.

  • BCL6 inhibitor 7

    A potent BCL6 protein-protein interaction inhibitor with Kd of 78 nM; exhibits an efficacy in cell-free and cellular PPI assays.